Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary...

Area of Science:

• Pulmonary Medicine
• Respiratory Physiology

Background:

• Dynamic hyperinflation (DH) is a key issue in COPD, worsening breathlessness during exercise.
• Understanding how bronchodilators affect DH and breathlessness is crucial for managing COPD.

Purpose of the Study:

• To investigate the impact of inhaled beta-agonist therapy on dynamic hyperinflation during exercise in COPD patients.
• To explore the relationship between changes in DH and perceived breathlessness.

Main Methods:

• 13 COPD patients underwent pulmonary function tests and exercise assessments (breathlessness, lung volumes, pressures) with placebo and albuterol.
• Dynamic hyperinflation was assessed by measuring end-expiratory lung volumes (EELV) and end-inspiratory lung volumes (EILV).
• Inspiratory pressure reserve and neuroventilatory coupling were evaluated using esophageal pressure measurements.

Main Results:

• Albuterol significantly improved FEV1 and FVC, reduced exercise-induced dynamic hyperinflation (lower EELV/TLC and EILV/TLC), and increased inspiratory pressure reserve.
• Significant improvements in neuroventilatory coupling and a reduction in Borg breathlessness scores were observed.
• Reduced DH and improved neuroventilatory coupling strongly correlated with decreased breathlessness.

Conclusions:

• Inhaled bronchodilators effectively reduce exercise-induced dynamic hyperinflation in COPD patients.
• Improvements in inspiratory pressure reserve and neuroventilatory coupling contribute to reduced breathlessness.
• Changes in dynamic hyperinflation and breathing control are primary drivers of breathlessness relief in COPD.